104 related articles for article (PubMed ID: 21735964)
1. Parametric modelling of survival following HIV and AIDS in the era of highly active antiretroviral therapy: data from Australia.
Nakhaee F; Law M
East Mediterr Health J; 2011 Mar; 17(3):231-7. PubMed ID: 21735964
[TBL] [Abstract][Full Text] [Related]
2. Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981-2003.
Nakhaee F; Black D; Wand H; McDonald A; Law M
Sex Health; 2009 Jun; 6(2):129-34. PubMed ID: 19457292
[TBL] [Abstract][Full Text] [Related]
3. HIV surveillance--United States, 1981-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jun; 60(21):689-93. PubMed ID: 21637182
[TBL] [Abstract][Full Text] [Related]
4. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
5. Predicting AIDS deaths and prevalence in Australia.
Solomon PJ; Wilson SR
Med J Aust; 1992 Jul; 157(2):121-5. PubMed ID: 1630375
[TBL] [Abstract][Full Text] [Related]
6. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
7. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
8. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.
Jain MK; Skiest DJ; Cloud JW; Jain CL; Burns D; Berggren RE
Clin Infect Dis; 2003 Apr; 36(8):1030-8. PubMed ID: 12684916
[TBL] [Abstract][Full Text] [Related]
9. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders.
Mijch A; Burgess P; Judd F; Grech P; Komiti A; Hoy J; Lloyd JH; Gibbie T; Street A
HIV Med; 2006 May; 7(4):205-12. PubMed ID: 16630032
[TBL] [Abstract][Full Text] [Related]
10. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of 30-day postoperative mortality in HIV/AIDS patients in the era of highly active antiretroviral therapy.
Wiseman SM; Forrest JI; Chan JE; Zhang W; Yip B; Hogg RS; Lima VD; Montaner JS
Ann Surg; 2012 Jul; 256(1):170-6. PubMed ID: 22580943
[TBL] [Abstract][Full Text] [Related]
12. The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994.
Commun Dis Rep CDR Rev; 1996 Jan; 6(1):R1-21. PubMed ID: 8581117
[TBL] [Abstract][Full Text] [Related]
13. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.
Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Lin CC; Huang LY; Chen MY; Hwang JS; Wang JD; Chuang CY
QJM; 2007 Feb; 100(2):97-105. PubMed ID: 17277317
[TBL] [Abstract][Full Text] [Related]
14. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
15. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
[TBL] [Abstract][Full Text] [Related]
17. AIDS-associated cancers: an emerging challenge.
Phatak UA; Joshi R; Badakh DK; Gosavi VS; Phatak JU; Jagdale RV
J Assoc Physicians India; 2010 Mar; 58():159-62. PubMed ID: 20848813
[TBL] [Abstract][Full Text] [Related]
18. Trends of AIDS in Guadeloupe (French West Indies) a longitudinal survey from 1988 to 1997.
Deloumeaux J; Foucan L; Sow-Goerger MT; Contamin B; Strobel M
West Indian Med J; 2000 Jun; 49(2):148-53. PubMed ID: 10948855
[TBL] [Abstract][Full Text] [Related]
19. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.
García de Olalla P; Martínez-González MA; Caylà JA; Jansà JM; Iglesias B; Guerrero R; Marco A; Gatell JM; Ocaña I;
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1051-7. PubMed ID: 12546112
[TBL] [Abstract][Full Text] [Related]
20. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
